mRNA Display Reaches for the Clinic with New PCSK9 Inhibitor

Merck & Co. recently reported one of the first mRNA display-derived clinical candidates in a bioavailable inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). Herein, we discuss the chemical and pharmacological challenges surmounted in bringing this compound to trials and the current outlook for mRNA display-based therapeutic development.

Automated summary

In this article, we discuss the successful development of an mRNA display-derived clinical candidate by Merck & Co., which is a bioavailable inhibitor of proprotein convertase subtilisin/kexin type 9 (PCSK9). The challenges in the chemical and pharmacological aspects of bringing this compound to trials are highlighted, and the current outlook for mRNA display-based therapeutic development is examined.